Seven Bridges Advisors LLC reduced its position in Allergan PLC (NYSE:AGN) by 3.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,740 shares of the company’s stock after selling 153 shares during the period. Seven Bridges Advisors LLC’s holdings in Allergan PLC were worth $864,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the company. TIAA CREF Investment Management LLC raised its position in Allergan PLC by 11.6% in the first quarter. TIAA CREF Investment Management LLC now owns 4,228,619 shares of the company’s stock worth $1,133,397,000 after buying an additional 437,912 shares in the last quarter. Geode Capital Management LLC raised its position in Allergan PLC by 1.9% in the first quarter. Geode Capital Management LLC now owns 3,238,971 shares of the company’s stock worth $866,405,000 after buying an additional 60,819 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in Allergan PLC by 7.7% in the first quarter. UBS Asset Management Americas Inc. now owns 3,232,147 shares of the company’s stock worth $866,313,000 after buying an additional 231,603 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in Allergan PLC by 78.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,245,934 shares of the company’s stock worth $333,948,000 after buying an additional 547,759 shares in the last quarter. Finally, Teachers Advisors Inc. raised its position in Allergan PLC by 6.6% in the first quarter. Teachers Advisors Inc. now owns 1,040,821 shares of the company’s stock worth $278,971,000 after buying an additional 64,625 shares in the last quarter. 85.19% of the stock is currently owned by institutional investors.

Allergan PLC (NYSE:AGN) traded down 0.11% during mid-day trading on Wednesday, hitting $238.41. The stock had a trading volume of 3,967,320 shares. The firm’s 50-day moving average price is $245.19 and its 200-day moving average price is $243.01. The stock has a market cap of $94.40 billion, a PE ratio of 22.70 and a beta of 0.73. Allergan PLC has a 1-year low of $195.50 and a 1-year high of $322.68.

Allergan PLC (NYSE:AGN) last posted its quarterly earnings data on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The firm earned $3.68 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same period last year, the company posted $4.41 EPS. The business’s quarterly revenue was up 1.0% on a year-over-year basis. On average, equities analysts expect that Allergan PLC will post $14.01 earnings per share for the current year.

A number of research firms have recently weighed in on AGN. Mizuho restated a “buy” rating and set a $305.00 target price on shares of Allergan PLC in a research report on Wednesday, September 14th. Bank of America Corp. set a $294.00 target price on Allergan PLC and gave the stock a “buy” rating in a research report on Tuesday. Piper Jaffray Cos. restated a “hold” rating and set a $236.00 target price on shares of Allergan PLC in a research report on Saturday, June 18th. Credit Suisse Group AG set a $322.00 target price on Allergan PLC and gave the stock a “hold” rating in a research report on Wednesday, August 3rd. Finally, Vetr downgraded Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $275.94 target price for the company. in a research report on Thursday, June 2nd. Seven equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Allergan PLC currently has a consensus rating of “Buy” and an average target price of $308.54.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).

Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.